25 April, 2008 - UCB today announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMEA has issued a positive opinion recommending that the European Commission grants a marketing authorisation for Neupro® (rotigotine transdermal patch) in the symptomatic treatment of moderate-to-severe idiopathic Restless Legs Syndrome (RLS) in adults.
The details can be read here.
No comments:
Post a Comment